Europe: The European Medicines Agency is a step closer to expansion following European Parliament approval

In brief

On 15 June 2021, after an initial consensus from health ministers in Luxembourg, the European Parliament's health committee approved an extension of the European Medicines Agency's (EMA) mandate. The proposed regulation, which is part of a larger European Health Union package, passed with 68 voting in favor, three against and eight abstaining. As a result, the proposal will likely advance to the trilogue stage with a view to being adopted during the July plenary session. Key features of the regulation are summarized below. 


Contents

Emergency response 

The absence of a clear legal framework guiding the response to the pandemic and inadequate preparation has impacted the majority of the member states. The regulation would increase the EMA's capacity to respond to emergencies by creating an emergency task force that would be authorized to issue recommendations for medical products during health crises and to advise on clinical trials. 

 

Drug monitoring 

The report by the Committee on the Environment, Public Health and Food Safety (ENVI) [JBP1] proposed a "European medicines supply database," which would be updated in real time to counter the drug shortages that plagued the pandemic. In the report, the committee emphasized the need to improve coordination to quickly address threats to public health and maintain a "one health" approach across the European Union (EU). The pandemic has exposed the complex international supply chains servicing the EU's drug and medical device market, with export restrictions and border closures impeding deliveries. The report advocates a long-term approach to planning to prevent bottlenecks during emergencies. The EMA would use an electronic platform to gather data from wholesale distributors, marketing authorization holders and member states to coordinate access to medical products. This is inspired by successful projects such as CISMED[JBP2] , which was also funded by the EU. 

 

Clinical trials 

The EMA plans to carry out clinical trials on a larger scale through a proposed clinical trials information system. The move is inspired by larger trials such as the "UK RECOVERY" trial, which was crucial to battling COVID-19.

 

Data protection

In agreeing changes to the original mandate, members of the European Parliament clarified that the handling of personal data collected during the formation and execution of emergency response provisions will be subject to EU data protection rules. 

 

For further information, please contact Julia Gillert or Marilyn Acquah of our London office.

 

************

 

 

Sources

CISMED: Future plans for scaling up the information on medical shortages at supranational level CISMED — DigitalHealthEurope

Council of Europe press release (15 June 2021): Council agreement paves way to reinforce European Medicines Agency — Consilium (europa.eu)

Council of Europe press release (11 November 2020): Building a European Health Union (europa.eu)

Draft report on the proposal for a regulation of the European Parliament and of the Council on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (March 2021[JBP3] ): PR_COD_1amCom (europa.eu)

Extension of the mandate of the European Medicines Agency (EMA) by Nicole Scholz (21 May 2021): EMA mandate extension | Legislative train schedule | European Parliament (europa.eu)

POLITICO Pro Health Care Alert: Parliament's health committee OKs EMA mandate expansion by Carlo Martuscelli (22 June 2021)

Proposal for a regulation of the European Parliament and of the Council (11 November 2020): EMA text 3 November PM2 clean (europa.eu)

Outcome of proceedings (16 June 2021): pdf (europa.eu)

 

 

Contact Information

Copyright © 2022 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.